Despite several recommendations for standardization of multiparameter flow cytometry (MFC) the number, specificity and combinations of reagents used by diagnostic laboratories for the diagnosis and classification of acute leukemias (AL) are still very diverse. Furthermore, the current diagnostic interpretation of flow cytometry readouts is influenced arbitrarily by individual experience and knowledge. We determined the potential value of a minimal four-color combination panel of 13 monoclonal antibodies (mAbs) with a CD45/sideward light scattergating strategy for a standardized MFC immunophenotyping of the clinically most relevant subgroups of AL. Bone marrow samples from 155 patients with acute myeloid leukemia (AML, n ¼ 79), B-cell precursor acute lymphoblastic leukemia (BCP-ALL, n ¼ 29), T-cell precursor acute lymphoblastic leukemia (T-ALL, n ¼ 12) and normal bone marrow donors (NBMD, n ¼ 35) were analyzed. A knowledge-based learning algorithm was generated by comparing the results of the minimal panel with the actual diagnosis, using discriminative function analysis. Correct classification of the test sample according to lineage, that is, BCP-ALL, T-ALL, AML and differentiation of NBMD was achieved in 97.2% of all cases with only six of the originally applied 13 mAbs of the panel. This provides evidence that discriminant function analysis can be utilized as a decision support system for interpretation of flow cytometry readouts.
Introduction
In recent years, flow cytometric immunophenotyping has evolved from indirect immunofluorescence techniques to a complex multiparametric diagnostic tool, which is indispensable for the diagnosis of acute leukemias (AL).
1,2 Recent developments in flow cytometry technologies including fluidics, lasers, optics, analog and digital electronics, computers, software, fluorochromes and antibodies have facilitated the comprehensive use of multiparametric flow cytometry immunophenotyping, allowing for an objective analysis of high numbers of cells on a single cell level in a relatively short period of time. 3, 4 With the use of three-and four-color immunophenotyping, simultaneous measurement of five or six different parameters is now routinely applied for the diagnosis of AL in most clinical laboratories. 5, 6 The complexity of five-and sixparameter analyses and the interpretation of the data rely to a great extent on standardization and validation of the instrument, the reagents and the procedure. [7] [8] [9] Furthermore, the current diagnostic interpretation of flow cytometry readouts can be influenced arbitrarily by individual experience and knowledge. One of the basic requirements regarding reagents is the careful selection of antibody combinations to perform a fast, reliable and clinically useful analysis of the leukemic cell clones. [10] [11] [12] However, in the time of growing financial pressure on health care systems, economic considerations must also be taken into account. Although several recommendations and guidelines addressing the selection of antibodies for flow cytometric analysis of ALs have been published during the last years, the reagent combinations used by laboratories engaged in immunophenotyping of AL remain very diverse. 10, 13 In view of the complexity of multiparameter techniques and the multitude of available monoclonal antibodies (mAbs), inconsistencies in the criteria for choosing and combining antibodies are not surprising. Preferences may depend on several factors including the experience and training of the laboratory professional, the specific settings of the laboratory (e.g., hospital-based vs reference laboratory), the volume of the specimen analyzed and the type of sample (bone marrow (BM) vs peripheral blood or lymphoid tissue). 12 The composition of most antibody panels has been more or less influenced by these factors, and none of these panels has been validated or tested for its diagnostic accuracy in a multicenter trial.
We hypothesized that a standardized minimal four-color screening panel in combination with a CD45/sideward light scatter (SSC)-gating strategy can be utilized in a multicenter trial to build a knowledge-based supervised learning algorithm, supporting the interpretation of flow cytometry readouts for the diagnosis of AL.
To this end, we constructed a screening panel composed of 13 mAbs to provide general information on the sample (AL vs. no leukemia) and lineage assignment of the respective leukemia (acute myeloid leukemia (AML) vs. B-cell precursor acute lymphoblastic leukemia (BCP-ALL) vs. T-cell precursor acute lymphoblastic leukemia (T-ALL)). Further aims of this multicenter study were to address (1) the relative value of each 'lineage-associated' marker for the definition of myeloid, B-and T-cell lineages, (2) to establish the best combination of markers for the definition of each of these three lineages and (3) to define the need for using further markers for lineage assignment in AL. We used discriminative function analysis as a linear stepwise regression model to generate a knowledge-based learning algorithm by comparing the results of the minimal panel with the actual diagnosis determined with a more elaborate and comprehensive diagnostic approach, including cytomorphology and cytochemistry as well as extensive multiparameter immunophenotyping performed separately in each center.
Materials and methods

Patients and laboratories
Eight European laboratories participated in the study. Between April 2000 and June 2001, a total of 155 consecutive samples from adults and children were analyzed. These included samples from 29 patients with BCP-ALL and 79 patients with AML, including the following WHO subtypes: five patients with recurrent genetic abnormalities, two with t(8;21) and three with t(15;17) and one with multilineage dysplasia, following a myelodysplastic syndrome. The remaining patients belonged to the not otherwise categorized WHO subtype, including: 10 with minimal differentiation, 21 without maturation, 13 with maturation, 15 with myelomonocytic AL, 10 with monoblastic and monocytic leukemias, 2 with acute erythroid leukemias and 2 with megakaryoblastic leukemias. Furthermore, 12 patients with precursor T-cell ALL (T-ALL) and 35 with normal bone marrow donors (NBMD) were recruited. From all individuals or their guardians, informed consent was obtained according to the requirements of the local ethical committees. BM from healthy donors was obtained as part of the workup for allogeneic hematopoietic cell donation. Flow cytometry was performed using either Beckman Coulter XL flow cytometers (Beckman Coulter, Miami, FL, USA) (three centers; 70 individuals, including 17 patients with BCP-ALL, 32 with AML, six with T-ALL and 15 with NBMD) or FACSCalibur flow cytometers (BD Biosciences, San Jose, CA, USA) (five centers; 85 individuals, including 12 with BCP-ALL, 47 with AML, six with T-ALL and 20 with NBMD).
Samples
BM aspirates, which contained more than 30% blast cells by morphology, were obtained at diagnosis before any chemotherapeutic treatment. The samples had been anticoagulated with ethylenediaminetetraacetic acid or heparin. All samples were passed twice through a 25 mm gauge syringe for the homogenization of the distribution of BM blast cells in the sample. Cell count was performed to adjust the cell number to a final count of 10 7 cells/ml. All samples were processed and analyzed within 24 h after BM aspiration, and before sample preparation, sample quality was evaluated by conventional cytomorphology.
Staining for surface antigens
Two tubes were stained exclusively for surface antigens with the following antibody combinations for FACSCalibur users: fluorescein isothiocynate (FITC)/phycoerythrin (PE)/PE-cyanin5(PC5)/ allophycocyanin (APC) -(1) CD7 (BD Biosciences; 10 ml undiluted)/CD22 (BD Biosciences; 10 ml undiluted)/CD45 (Immunotech Marseille, France; 10 ml 1/10 diluted with phosphatebuffered saline (PBS)/CD33 (Immunotech; 5 ml undiluted) and (2) CD15 (BD Biosciences; 10 ml undiluted)/CD13 (BD Biosciences; 10 ml undiluted)/CD45 (Immunotech; 10 ml 1/10 diluted)/CD34 (BD Biosciences; 5 ml undiluted). For XL users, the combinations were as follows: FITC/PE/PE-Texas red (ECD)/PC5 -(1) CD7 (BD Biosciences; 10 ml undiluted)/CD22 (BD Biosciences; 10 ml undiluted)/CD45 (Immunotech; 10 ml undiluted)/CD33 (Immunotech; 10 ml undiluted) and (2) CD15 (BDB; 10 ml undiluted)/ CD13 (BDB; 10 ml undiluted)/CD45 (Immunotech; 10 ml undiluted)/CD34 (Immunotech; 10 ml undiluted). A third tube was processed in parallel to measure the autofluorescence levels of the blast cells; this later tube was only stained with CD45-PC5 (Immunotech; 10 ml 1/10 diluted) for FACSCalibur users and CD45-ECD (Immunotech; 10 ml undiluted) for XL users.
Antibody titration experiments (in PBS) were performed beforehand for the calculation of the appropriate amount of antibody in each combination, which was defined as the combination of maximum saturation and minimum background staining. Antibodies were placed separately into each tube before 100 ml of PBS-diluted BM sample containing 10 6 nucleated cells was added. Tubes were gently mixed for 10 s and incubated at room temperature (RT) in the dark for 15 min. After addition of 2 ml/tube of Quicklysis (Cytognos, Salamanca, Spain) and gentle vortexing, the tubes were incubated a second time for 10 min in the dark (RT). Then they were centrifuged once for 5 min at 500 g and the supernatant discarded. The cell pellet was resuspended in 2 ml/tube of filtered PBS and centrifuged again at 500 g for 5 min; afterward, the supernatant was discarded with a Pasteur pipette and the cell pellet was resuspended in 0.5 ml/tube of filtered PBS containing 1% paraformaldehyde. Flow cytometric acquisition of the sample was performed either immediately or within 24 h after storage at 4 1C. All mAbs were centrally obtained, aliquoted and distributed to each participating center.
Simultaneous staining for surface and cytoplasmic antigens
Two tubes were stained simultaneously for surface and cytoplasmic antigens with the following antibody combinations for FACSCalibur users (FITC/PE/PC5/APC): (1) cyCD3 (Dako, Glostrup, Denmark; 5 ml undiluted)/cyCD79a (Dako; 10 ml undiluted)/CD45 (Immunotech; 10 ml 1/10 diluted)/CD117 (BDB; 3 ml undiluted) and (2) CD19 (Dako; 10 ml undiluted)/ cyMPO (Dako; 3 ml undiluted)/CD45 (Immunotech; 10 ml 1/10 diluted)/CD5 (BD Biosciences; 5 ml undiluted). For XL users, the combinations were as follows (FITC/PE/ECD/PC5): (1) cyCD3 (Dako; 5 ml undiluted)/cyCD79a (Dako; 10 ml undiluted)/CD45 (Immunotech; 10 ml undiluted)/CD117 (Immunotech; 5 ml undiluted) and (2) CD19 (Dako; 10 ml undiluted)/cyMPO (Dako; 3 ml undiluted)/CD45 (Immunotech; 10 ml undiluted)/CD5 (Immunotech; 5 ml undiluted). A third tube was processed in parallel to measure the autofluorescence levels of the blast cells; this later tube was only stained with CD45-PC5 (Immunotech; 10 ml 1/10 diluted) for FACSCalibur users and CD45-ECD (Immunotech; 10 ml undiluted) for Coulter XL instrument users. All mAbs were centrally obtained, aliquoted and distributed to each participating center. The Fix & Perm reagent kit (Caltag Laboratories, San Francisco, CA, USA) was used for cell fixation and permeabilization, strictly following the recommendations of the manufacturer, after staining for surface markers.
Standard protocol for instrument setup and color compensation 14, 15 First, fluidics were rinsed and -for the FACSCalibur instrumentthe time delay calibration was performed according to the manufacturer's instructions. The amplification modes and threshold were defined as follows: forward light scatter (FSC) and SSC were expressed on a linear amplification scale. Fluorescence (FL) intensities were expressed as relative linear channels on a four-decade logarithmic scale. FSC threshold was set in channel 52 on a linear scale of 1024 histogram channels. For the appropriate positioning of the FSC vs. SSC window of analysis, a representative unstained cell suspension (e.g., whole blood) was run and FSC photodiode amplifier gain and SSC photomultiplier (PMT) settings were adjusted so that all relevant populations (neutrophils, monocytes, lymphocytes and blast cells) fell on scale. After selection of the lymphocyte population, the PMT settings for each FL parameter were adjusted, so that the unstained lymphocytes were placed in the first log decade, slightly away from the axes with all compensation settings at zero. Fluorescent reference beads (RFP-60-1, Spherotech (Libertyville, IL, USA)) were run under the obtained FL PMT settings with electronic compensation settings still at zero, and the mean channels for the four FL channels were recorded after acquisition of 5000 singlet beads. These channels represented the 'applicationspecific initial target channels' for subsequent instrument setup procedures.
Color compensation settings were performed with four singlecolor tubes (i.e., CD8-FITC, CD8-PE, CD8-PC5 or ECD, CD8-APC or PC5) stained according to the respective fluorochrome combination for FACSCalibur or Coulter XL users. Lymphocytes were selected by FSC vs. SSC gating, and the parameters for electronic compensation adjusted, such that the mean FL channel of the CD8 negative and CD8 bright lymphocyte population in the nondetecting FL channels were identical710 channels. A control tube with CD3-FITC/CD19-PE/CD4-PC5 or ECD/CD8-PC5 or APC for FL channels 1 to 4, respectively, was run afterward to verify the following criteria for appropriate compensation circuits:
negative . The fluorescent reference beads were acquired once more with the obtained instrument settings and with the electronic compensation settings activated. The mean channels obtained for each FL detector represent the 'application-and instrument-specific target channels' for subsequent controls of the positioning of the FL window of analysis. For subsequent instrument controls, RFP-60-1 beads were acquired before each experiment, and the mean FL channels of the reference beads were plotted in Levey-Jennings charts. Adjustment of PMT settings and color compensation was only performed if the reference beads repeatedly fell outside tolerance zones according to Westgard's rules. 16 According to the guidelines formulated by the European Working Group of Clinical Cell Analysis, instrument performance with respect to FL intensity measurements was checked periodically by running calibration beads (i.e., a 1:1 mixture of Spherotech RCP-30-1L (containing three lowintensity peaks) and RCP-30-1H (containing four high-intensity peaks) as well as a blank bead (Spherotech BCP-60-1). Using this procedure, the participating laboratories were able to verify that background FL was on scale, and that the four instrument performance parameters for FL intensity measurements were within specifications.
Flow cytometric data analysis
Each site consecutively acquired leukemic and nonleukemic samples for the trial, and generated list mode data (LMD) on these samples. The LMD were analyzed centrally using EXPO32 software (Beckman Coulter). For data analysis, we utilized the CD45/SSC-gating strategy. 17, 18 The protocol consisted of bivariate dot plots for both surface and intracellular stainings including (1) FSC/SSC; (2) CD45/SSC was used to characterize the cell population within the (Table 1) Blasts  83  34  97  77  22  95  81  23  96  4  2  23  CD3  1  0  46  1  0  94  97  63  99  8  1  52  CD5  1  0  25  1  0  80  87  34  99  6  0  43  CD7  0  0  12  2  0  91  87  1  100  6  1  35  CD79a  85  4  99  3  0  40  3  0  93  26  1  74  CD19  54  5  99  1  0  100  0  0  3  14  0  57  CD22  91  22  99  1  0  51  1  0  4  18  0  62  CD13  20  0  98  82  0  99  5  0  94  39  6  63  CD33  1  0  28  61  0  99  1  0  6  23  0  51  CD15  2  0  39  22  0  99  1  0  58  18  1  41  MPO  3  0  31  31  0  100  2  0  27  33  0  93  CD34  77  0  99  49  0  99  1  0  94  28  6  74  CD117  0  0  6  38  0  93  1  0  46  11  1  41  CD45  96  1  100  100  0  100  100  100  100  100  84  100 Abbreviations: AML, acute myeloid leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; T-ALL, T-cell precursor acute lymphoblastic leukemia. 
Statistical methods
Discriminant function analysis (DFA) is a linear stepwise regression model to predict group membership from a set of predictors. The primary goals of DFA are to find the dimension or dimensions along which groups differ, and to find classification functions to predict group membership. 19 In regard to this study, the question is whether a differential diagnosis among a group of patients with BCP-ALL, T-ALL, AML and a group of normal control persons can be made reliably from a set of predictors, namely CD expression values (percentage of positive cells) within the CD45 low /SSC low gate. In a second step, DFA was used to define the specificity and the least number of the most discriminating predictors.
All statistical calculations and computations were performed with SPSS (version 12.0.1, SPSS Inc., Chicago, IL, USA) Classification was performed by leaving out a group of 72 randomly assigned cases -test sample (Table 2) . DFA was performed on the remaining 83 cases -learning sample. Three canonical discriminant functions were derived producing the unstandardized discriminant coefficients (c j ) used in equation (1) for making the classification.
Four classification scores, one for each group, were calculated for each case by applying the basic linear classification equation for the jth group (j ¼ 1,2,...,k)
A score for the classification formula for group j (C j ) is found by multiplying the raw score on each predictor (X) by its associated discriminant coefficient (c j ), summing over all predictors, and adding a constant c j0 .
The classification scores for each case and each of the four diagnostic groups were calculated and each case of the test sample was assigned to the group for which it had the highest classification score. Predicted classification and actual diagnosis of the test sample are compared in the classification table (Table 3) . Furthermore, discriminant scores were computed for each case and each of the three discriminant functions by multiplying the unstandardized discriminant coefficients by the raw score on each predictor, summing these products, and adding the constant. The position of each case within the threedimensional space of the DFA is defined by the three discriminant scores for each case as displayed in the discriminant function plot (Figure 2) .
To select the least number of predictors that most reliably distinguish between the four diagnostic groups, stepwise DFA was performed and Wilks' l was calculated at each step to assess the improvement in classification. At each step, the variable with the smallest Wilks' l was entered into the analysis. With this approach, variables that do not decrease overall Wilks' l do not improve classification and were removed from the analysis (Table 4) . Another way to study the usefulness of each 
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variable in the discriminant functions is provided by the structure matrix, which contains within-group correlations of each predictor variable with each of the canonical functions (Table 5) .
Results
The median percentage of blast cells defined within the CD45/ SSC-dot plot as proportion of CD45 low /SSC low cells was 83% for BCP-ALLL, 77% for AML, 81% for T-ALL and 4% for normal BM donors ( Table 1) .
The lineage-restricted antigens CD19, CD79a, CD22 for BCP-ALL; CD3, CD5, CD7 for T-ALL and CD13, CD33, MPO for Table 2 Distribution of cases in the randomly assigned test and learning sample Test sample learning  15  35  3  19  72  Sample  14  42  8  19  83  Total  29  77  11  38  155 Abbreviations: AML, acute myeloid leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; T-ALL, T-cell precursor acute lymphoblastic leukemia. Abbreviations: AML, acute myeloid leukemia; BCP-ALL, B-cell precursor acute lymphoblastic leukemia; T-ALL, T-cell precursor acute lymphoblastic leukemia. Rows represent the actual and columns the predicted sample classification. The percentage of cases on the diagonal is the percentage of correct classification -the hit ratio (97.2%). There are two misclassifications for two cases of actual AML, which were predicted to be NBMD. 
Diagnosis
BCP-ALL AML T-ALL Normal Total
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AML displayed a strong and selective expression pattern for the blast cell population of the respective leukemias, whereas in NBMD, the blast population showed a more heterogeneous and not clearly lineage-restricted expression of these markers. The co-expression of myeloid antigens on blast cells of some cases of ALL is reflected by a median percentage of positive cells for CD13 of 20% in BCP-ALL and 5% in T-ALL. The expression of the progenitor marker CD34 was not lineage restricted.
Remarkably, the blast cell population in the CD45/SSC-blast gate of NBMD contained a higher percentage of CD34 positive cells than in T-ALL patients. The expression of CD117, the second progenitor marker in the panel, was almost limited to AML, with a median percentage of positive cells of 38%. The median percentage of CD45 positive blast cells was relatively low for BCP-ALL with 96%, but 100% for AML, T-ALL and NBMD.
To prove the ability of the test panel to classify the four actual diagnostic groups correctly, the data set was randomly divided into a learning set with 83 cases, including the actual diagnosis for each case and a test sample comprising the remaining cases without the information of the actual diagnosis (Table 2) . DFA was first performed on the learning data set. Three discriminant functions were derived by SPPS providing the classification function coefficients. Each case of the test sample was then predictively classified according to the classification equations (1), and crosstable comparison of the actual diagnosis with the predicted classification showed that 97.2% of the original grouped cases were classified correctly (Table 3) . Only two cases with actual AML were predicted to be normal.
We further investigated whether the number of mAbs in the panel can be reduced without any loss of discriminant function and diagnostic accuracy. The test panel consisted of 13 different mAbs. These were used to generate 14 predictors: the percentage of cells within the CD45 low /SSC low gate and the percentage of positive cells within this gate for each of the 13 mAbs. The contribution of each predictor to the improvement of classification was evaluated by sequential DFA using Wilks' l. Only variables that minimized overall Wilks' l were included in the model ( Table 4 ). Variables that did not reduce overall Wilks' l were excluded from the analysis. According to this approach, only the variables CD22 and CD3, the percentage of cells within the CD45 low /SSC low gate, CD7, CD13, CD45 and CD5 were included. Thus, it became apparent that the original set of 14 predictors can be reduced to only 6 mAbs with a 'hit ratio' (correct classification) of 97.2% in the test sample.
To evaluate the usefulness of each variable for each of the three discriminant functions, the structure matrix displaying the within-group correlations of each predictor variable with each of the three canonical functions was studied (Table 5) . Each variable in the table is marked by an asterisk according to its largest correlation with one of the three canonical functions. The strongest correlations for CD3, CD5 and CD7 occur with function 1. CD22 and CD13 have their strongest correlation with function 2, whereas the percentage of cells within the CD45 low /SSC low gate correlates best with function 3 (Table 5 ). For each case, three discriminant scores according to each of the three discriminant functions were calculated. These discriminant score values were used to position each case within the three-dimensional DFA matrix in a scatter diagram (Figure 2 ). Each case is depicted as a beam ending in a colored dot, originating in the clearly separated group centroids.
We further considered the two misclassified cases of the test sample in more detail. Both cases were actually diagnosed as AML, by morphology and immunophenotyping, but the percentage of cells within the CD45 (Table 6) , it might explain that these two patients with low or threshold cell counts between 20 and 30% are predicted to be NBMD.
Discussion
Many efforts to standardize the interpretation of flow cytometry readouts in clinical flow cytometry undertaken in the past have been hampered by the complexity and variety of pre-and post-analytical methodology. One of the cornerstones of a standardized post-analytical concept is the CD45/SSC-gating strategy. 18, 20 Nonetheless, there still is an enormous diversity of different approaches, which become even more difficult to interpret with the introduction of three-to four-color or multiparameter flow cytometry (MFC).
Basically, there are three different methods for flow cytometry data interpretation: (1) Simplistic two-dimensional manual gating with Boolean combinations on flow cytometry readouts and sample classification based on individual knowledge and experience; (2) Sample classification using a computer-based automated multivariate learning algorithm generated by a twodimensional gating decision procedure and (3) Supervised classification with support vector machines (SVM) and automated in-silico gating of multivariate flow cytometry readouts.
Several study groups have proved that computational cluster analysis techniques or multivariate projection methods for the exploration of the data matrix generated by MFC immunophenotyping of acute myeloid or acute lymphoblastic leukemia is an adequate tool to identify phenotypic subgroups that correlate with biological, clinical or prognostic features of the disease. [21] [22] [23] [24] [25] Principal component analysis, a nonlinear computational multivariate analysis of flow cytometry antigen expression profiles has been successfully performed by De Zen et al. to identify patients with MLL/AF4 rearrangement in childhood acute lymphoblastic leukemia. 23 In a similar approach, using multidimensional cluster analysis of six-parameter flow cytometry data. Zamir et al. studied the cellular diversity of normal BM and resolved 23 subclasses of different cell populations inseparable by two-parameter scatter plots. 24 Valet et al. introduced a classification method for blood samples in flow cytometry, called algorithmic data sieving. 26 For each class of samples, a discretized representative is derived from a training data set. New samples are then classified according to their similarity to these representatives. In a recent study, Toedling et al. applied a multivariate classification technique using SVM. 27 Classifiers were built on conventionally diagnosed training data. Using automated in-silico detection of cell populations, the detection accuracy on an independent data set and analyzed marker expression of incongruently classified cells was assessed. This SVM-based classification recovers manually gated leukemic cells with 99.78% sensitivity and 98.87% specificity. Overall, these studies unequivocally demonstrate that multivariate analyses procedures are an adequate tool to support the diagnostic decision and sample classification based on flow cytometry data interpretation. The utilization of these approaches for computational LMD analysis for minimal residual disease detection is of course intriguing, but requires a large and meticulously controlled knowledge base with a long enough clinical follow-up for outcome analysis.
In this study, we evaluated the usefulness of a computational stepwise DFA for the sample classification of flow cytometry readouts based on a minimal four-color screening panel with a CD45/SSC-gating strategy to be used as a decision support system for a more accurate and reliable diagnostic analysis of AL.
For this purpose, we conducted a multicenter trial with a standardized minimal four-color antibody panel, which was tested for its usefulness for flow cytometry diagnosis of AL in comparison to the actual diagnosis made by a combination of cytomorphology, more comprehensive immunophenotyping, cytogenetics and molecular investigations. The requirements of the panel were specified in the first place to differentiate between samples of NBMD and patients with AL and secondly to distinguish the three main lineage affiliations of AL: BCP-ALL, T-ALL and AML.
The presently applied method of data analysis provided a data matrix containing the percentages of positive cells for 13 antigens and a fourteenth variable, the percentage of cells within the CD45 low /SSC low -gated cell population (Figure 1 ). This data matrix was used for computational stepwise DFA to determine a knowledge-based learning algorithm applicable for the predictive classification of an unknown test sample. Furthermore, DFA was used to determine the least number of variables, which most clearly discriminate between the four diagnostic groups, BCP-ALL, T-ALL, AML and NBMD. Using this approach, it became apparent that this panel was able to classify 97.2% of all cases from the test sample correctly. Moreover, variables were selected according to the Wilks' l method, and further analysis showed that only 7 (six mAbs and the percentage of cells within the CD45 low /SSC low gate) of the 14 variables were actually needed for classification. Importantly, the described approach for sample classification does not depend on arbitrarily chosen cutoff values, for example, 20% for surface markers and 10% for intracytoplasmic markers, commonly used to discriminate between positive and negative markers in leukemia classification. 28 In contrast to the panel proposal by the EGIL-group in 1995, mAbs for antigens like CD117, CD79a, MPO and CD15 are not considered to be necessary, although CD79a and MPO are lineage specific markers with an EGIL score value of two. 28, 29 This difference might be due to different prerequisites like the CD45/SSC-gating strategy utilized in the current study which is not part of the EGIL recommendations. We are aware of the fact that biphenotypic acute leukemias and subtypes of AML, BCP-ALL and T-ALL are not represented in this model. This is not only due to the relatively small sample size of 155, but also to the antibody composition of the panel which is, for example, not designed to diagnose CD1a positive cortical T-ALL or pre-B-ALL due to the lack of cytoplasmic IgM in the panel. To extend the current algorithm to map different subtypes of AL, a much larger knowledge-based learning sample with a more composite antibody panel would be needed.
In conclusion, we have shown proof of principle that DFA is an adequate method with the potential to be utilized as a decision support system for the diagnosis and classification of AL by MFC. Six mAbs and the CD45/SSC-gating strategy are sufficient to classify 97% of all patients with AL correctly in regard to lineage determination and differentiation of normals.
Besides, the economical implication might also influence future recommendations for a universal strategy to select antibodies and antibody combinations applicable to the analysis of hematological neoplasias.
